statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Aileron Therapeutics to be Included in the Russell Microcap Index

Aileron Therapeutics to be Included in the Russell Microcap Index Aileron Therapeutics to be Included in the Russell Microcap Index PR Newswire AUSTIN, Texas, July 1, 2024 AUSTIN, Texas, July 1, 2024...

Aileron Therapeutics Announces CFO Transition and Appointment

Aileron Therapeutics Inc (ALRN) has issued an update. Susan L. Drexler stepped down as the interim CFO and principal accounting officer of Aileron...

Aileron Therapeutics Announces CEO Transition

Current President and Chief Operating Officer, Brian Windsor, Ph.D., appointed Chief Executive Officer Dr. Windsor to lead Aileron into a new era focused on advancing a pipeline of first-in-class...

Aileron Therapeutics, Inc. (NASDAQ:ALRN) Short Interest Update

Aileron Therapeutics, Inc. (NASDAQ:ALRN  Get Free Report) saw a significant decline in short interest in February. As of February 15th, there was short interest totalling 31,200 shares, a...

Aileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader Event

Topline results from Phase 1b study of LTI-03, Aileron's novel Caveolin-1-related peptide in development for the treatment of idiopathic pulmonary fibrosis, expected in the second quarter of...

Aileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024

Panel discussion will highlight LTI-03, Aileron's novel Caveolin-1-related peptide, for the treatment of idiopathic pulmonary fibrosisWALTHAM, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Aileron...

Aileron Therapeutics trading resumes

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Aileron Therapeutics trading halted, volatility trading pause

Aileron Therapeutics files to sell 7.06M shares of common stock for holders

Aileron Therapeutics, Inc. (NASDAQ:ALRN) Sees Significant Increase in Short Interest

Aileron Therapeutics, Inc. (NASDAQ:ALRN  Get Free Report) saw a significant growth in short interest in January. As of January 15th, there was short interest totalling 48,100 shares, a growth...

Aileron Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.

Volume	57,641.00
52-Wk High	$7.42
52-Wk Low	$1.01

ALRN Aileron Therapeutics Inc

About

Feed

News

Fundamentals